This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipient (KTR). There is a dearth of standardized guidelines on optimal cardiovascular evaluation of transplant candidates. were found to have obstructive coronary artery disease (CAD).
The objective of this study is to examine the therapeutic efficacy of miR-133a-transfected bone marrow mesenchymal stem cells (BM-MSCs) in restoring damaged myocardium, reducing myocardial fibrosis, and improv.
BackgroundHuman pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) show tremendous promise for cardiac regeneration following myocardialinfarction (MI), but their transplantation gives rise to transient ventricular tachycardia (VT) in large-animal MI models, representing a major hurdle to translation.
In addition, to overcome the primary obstacle of poor retention and low survival after transplantation, a variety of studies have been dedicated to the engineering of ASCs with biomaterials. Besides, clinical trials have confirmed the safety and efficacy of ASCs therapy in the context of heart failure or myocardialinfarction.
Besides, keywords analysis revealed a strong emphasis on myocardialinfarction, therapy, and transplantation. Cluster analysis on references has highlighted the considerable interest in exosomes, extracellular vesicles, and microvesicles.
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardialinfarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardialinfarction remains poorly understood.
Although CHIP is known to increase the risk of myocardialinfarction and heart failure, the influence of CHIP in cardiac arrhythmias, such as atrial fibrillation (AF), is less explored.METHODS:CHIP prevalence was determined in the UK Biobank, and incident AF analysis was stratified by CHIP status and clone size using Cox proportional hazard models.
Although heart transplantation can replace the damaged heart, its clinical application and promotion are limited by the source of donor, expensive cost, immune rejection, and ethical problems. The main content of this paper is to explore the application of stem cells and gene technology in the treatment of myocardialinfarction (MI).
BackgroundEvidence guiding the pre‐hematopoietic stem cell transplantation (HSCT) cardiovascular evaluation is limited. The score was externally validated in a separate cohort of 919 HSCT recipients (mean age at transplant 54 years; 20.4%
Image courtesy of Hideki Kobayashi from Shinshu University milla1cf Tue, 04/30/2024 - 12:53 April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. However, the risk of arrhythmias following this procedure is reportedly high.
BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. Pretransplant cardiac testing may identify patients who require additional assessment before transplant or would benefit from risk optimization. years post-transplant. A minority had abnormal MPI (n=58, 15%).
BACKGROUND:In heart transplant recipients, right ventricular (RV) dysfunction may occur for a variety of reasons. Whether RV dysfunction in the stable phase after heart transplantation is associated with long-term adverse outcomes is unknown. years after heart transplantation were included. Over a median follow-up of 4.4
Heart failure, heart transplantation and death by cardiac causes were more often seen in individuals with biventricular phenotype compared to isolated left or right ventricular phenotype. Higher incidence of hot phases were noted in left ventricular and biventricular phenotypes.
Blood Transfusions and Organ Transplants: Though rare, the virus can be transmitted through infected blood or organ donations. HIV and Cardiovascular Disease: HIV infection itself is associated with an increased risk of cardiovascular disease and can double the risk of CVDs, including myocardialinfarction and stroke.
EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardialinfarction (MI). The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Presented at: ACC 2024.
The new trial, called DanGer Shock , is the first trial powered to examine whether the use of micro-axial flow pumps can improve survival in ST-elevation myocardialinfarctions (STEMI, the most serious type of heart attack) that are complicated by cardiogenic shock. Among 355 patients who were included in the analysis, 58.5%
Scott Rankin The Impact of Mitral Disease Etiology on Operative Mortality After Mitral Valve Operations The Annals of Thoracic Surgery November 2018 Alice Wang Robotic Mitral Valve Repair in Older Individuals: An Analysis of The Society of Thoracic Surgeons Database The Annals of Thoracic Surgery November 2018 Mohamad Alaeddine Aortic clamping strategy (..)
Scott Rankin The Impact of Mitral Disease Etiology on Operative Mortality After Mitral Valve Operations The Annals of Thoracic Surgery November 2018 Alice Wang 1 Robotic Mitral Valve Repair in Older Individuals: An Analysis of The Society of Thoracic Surgeons Database The Annals of Thoracic Surgery November 2018 Mohamad Alaeddine 1 Aortic clamping (..)
This Review explores the diverse roles of T cell subsets, including Th1, Th17, T cells, and Tregs, in myocardial inflammatory processes such as autoimmune myocarditis and myocardialinfarction.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content